SCLC,Extensive Stage
Conditions
Brief summary
This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy
Interventions
DRUGAdebrelimab
Treatment with adbelizumab
Sponsors
Henan Cancer Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Sign informed consent and join the study voluntarily; 2. Patients diagnosed with extensive small cell lung cancer; 3. Age ≥18 years old; 4. Have at least one measurable lesion (according to RECIST 1.1); 5. The investigators judged that adebrelimab treatment was acceptable; 6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;
Exclusion criteria
1. Allergic to adebrelimab and its excipients; 2. Patients who have also received other immune drugs or therapies; 3. Patients who are participating in other interventional studies; 4. patients with other malignant tumors; 5. Pregnant or lactating women; 6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety (Occurrence of ≥ Grade 3 AE) | End of each cycle (each cycle is 28 days) | The incidence of grade 3 or higher adverse events |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS | End of every two cycles (each cycle is 28 days) | Progression free survival |
| ORR | End of every two cycles (each cycle is 28 days) | Objective response rate |
| OS | End of every two cycles (each cycle is 28 days) | Overall survival |
| DCR | End of every two cycles (each cycle is 28 days) | Disease control rate |
Outcome results
None listed